Status:
COMPLETED
Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated
Lead Sponsor:
Allergan
Conditions:
Glaucoma, Open-Angle
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
This study will evaluate the safety and efficacy of bimatoprost/timolol fixed combination (GANfort®) versus latanoprost (Xalatan®) in patients with open-angle glaucoma who have never been previously t...
Eligibility Criteria
Inclusion
- Diagnosis of primary open-angle glaucoma that has never been treated
- Visual Acuity 20/60 or better in each eye
Exclusion
- Eye surgery within 3 months
- Any refractive eye surgery
- Contraindication to beta-adrenoceptor antagonist therapy (eg, chronic obstructive pulmonary disease \[COPD\], bronchial asthma, sinus bradycardia, heart block, history of severe myocardial infarction \[heart attack\])
- Eye inflammation or eye infection within 3 months
- Eye trauma within 6 months
- Oral, injectable, or topical ophthalmic steroids within 21 days or anticipated use during study
Key Trial Info
Start Date :
June 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 14 2012
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT01243567
Start Date
June 1 2010
End Date
February 14 2012
Last Update
April 18 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Coimbra, Portugal
2
Madrid, Spain